Ongentys FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved April 24, 2020)
Brand name: Ongentys
Generic name: opicapone
Dosage form: Capsules
Company: Neurocrine Biosciences, Inc.
Treatment for: Parkinson's Disease
Ongentys (opicapone) is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
Development timeline for Ongentys
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.